These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 20171768)
1. Significance of JAK2 and TET2 mutations in myelodysplastic syndromes. Hellström-Lindberg E Blood Rev; 2010 Mar; 24(2):83-90. PubMed ID: 20171768 [TBL] [Abstract][Full Text] [Related]
2. Mutation in TET2 in myeloid cancers. Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426 [TBL] [Abstract][Full Text] [Related]
3. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Tefferi A Leukemia; 2010 Jun; 24(6):1128-38. PubMed ID: 20428194 [TBL] [Abstract][Full Text] [Related]
4. The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Olcaydu D; Rumi E; Harutyunyan A; Passamonti F; Pietra D; Pascutto C; Berg T; Jäger R; Hammond E; Cazzola M; Kralovics R Haematologica; 2011 Mar; 96(3):367-74. PubMed ID: 21173100 [TBL] [Abstract][Full Text] [Related]
5. A common genetic mechanism in malignant bone marrow diseases. Levine RL; Carroll M N Engl J Med; 2009 May; 360(22):2355-7. PubMed ID: 19474434 [No Abstract] [Full Text] [Related]
6. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Schaub FX; Looser R; Li S; Hao-Shen H; Lehmann T; Tichelli A; Skoda RC Blood; 2010 Mar; 115(10):2003-7. PubMed ID: 20061559 [TBL] [Abstract][Full Text] [Related]
7. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Kosmider O; Gelsi-Boyer V; Slama L; Dreyfus F; Beyne-Rauzy O; Quesnel B; Hunault-Berger M; Slama B; Vey N; Lacombe C; Solary E; Birnbaum D; Bernard OA; Fontenay M Leukemia; 2010 May; 24(5):1094-6. PubMed ID: 20376084 [No Abstract] [Full Text] [Related]
8. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Smith AE; Mohamedali AM; Kulasekararaj A; Lim Z; Gäken J; Lea NC; Przychodzen B; Mian SA; Nasser EE; Shooter C; Westwood NB; Strupp C; Gattermann N; Maciejewski JP; Germing U; Mufti GJ Blood; 2010 Nov; 116(19):3923-32. PubMed ID: 20693430 [TBL] [Abstract][Full Text] [Related]
9. Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis. Flach J; Dicker F; Schnittger S; Kohlmann A; Haferlach T; Haferlach C Haematologica; 2010 Mar; 95(3):518-9. PubMed ID: 19903679 [No Abstract] [Full Text] [Related]
10. Prognostic significance of TET2 mutations in myelodysplastic syndromes: A meta-analysis. Guo Z; Zhang SK; Zou Z; Fan RH; Lyu XD Leuk Res; 2017 Jul; 58():102-107. PubMed ID: 28521175 [TBL] [Abstract][Full Text] [Related]
12. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features. Wang SA; Hasserjian RP; Loew JM; Sechman EV; Jones D; Hao S; Liu Q; Zhao W; Mehdi M; Galili N; Woda B; Raza A Leukemia; 2006 Sep; 20(9):1641-4. PubMed ID: 16871284 [No Abstract] [Full Text] [Related]
13. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia. Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812 [TBL] [Abstract][Full Text] [Related]
14. [Mutation of tet2 gene and malignant blood disease]. Qian XF; Shen YF; Zhang SJ; Li JY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):1096-100. PubMed ID: 20723337 [TBL] [Abstract][Full Text] [Related]
15. Acquired mutations in TET2 are common in myelodysplastic syndromes. Langemeijer SM; Kuiper RP; Berends M; Knops R; Aslanyan MG; Massop M; Stevens-Linders E; van Hoogen P; van Kessel AG; Raymakers RA; Kamping EJ; Verhoef GE; Verburgh E; Hagemeijer A; Vandenberghe P; de Witte T; van der Reijden BA; Jansen JH Nat Genet; 2009 Jul; 41(7):838-42. PubMed ID: 19483684 [TBL] [Abstract][Full Text] [Related]
16. Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis. Jeong JJ; Gu X; Nie J; Sundaravel S; Liu H; Kuo WL; Bhagat TD; Pradhan K; Cao J; Nischal S; McGraw KL; Bhattacharyya S; Bishop MR; Artz A; Thirman MJ; Moliterno A; Ji P; Levine RL; Godley LA; Steidl U; Bieker JJ; List AF; Saunthararajah Y; He C; Verma A; Wickrema A Cancer Discov; 2019 Jun; 9(6):778-795. PubMed ID: 30944118 [TBL] [Abstract][Full Text] [Related]
17. [Mutations in TET2 in myeloid cancers]. Bernard OA; Delhommeau F; Fontenay M; Vainchenker W Med Sci (Paris); 2009 Oct; 25(10):785-8. PubMed ID: 19849974 [No Abstract] [Full Text] [Related]
18. The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients. Ohyashiki K; Aota Y; Akahane D; Gotoh A; Miyazawa K; Kimura Y; Ohyashiki JH Leukemia; 2005 Dec; 19(12):2359-60. PubMed ID: 16239910 [No Abstract] [Full Text] [Related]
19. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Steensma DP; Dewald GW; Lasho TL; Powell HL; McClure RF; Levine RL; Gilliland DG; Tefferi A Blood; 2005 Aug; 106(4):1207-9. PubMed ID: 15860661 [TBL] [Abstract][Full Text] [Related]
20. Mutation in TET2 in myeloid cancers. Tefferi A; Lim KH; Levine R N Engl J Med; 2009 Sep; 361(11):1117; author reply 1117-8. PubMed ID: 19741235 [No Abstract] [Full Text] [Related] [Next] [New Search]